ORIC PHARMACEUTICALS INC
NASDAQ: ORIC (Oric Pharmaceuticals, Inc.)
Last update: 11 hours ago9.03
-0.38 (-4.04%)
| Previous Close | 9.41 |
| Open | 9.10 |
| Volume | 808,371 |
| Avg. Volume (3M) | 1,178,595 |
| Market Cap | 769,522,112 |
| Price / Book | 3.65 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 3.97% |
| Current Ratio (MRQ) | 12.00 |
| Operating Cash Flow (TTM) | -115.01 M |
| Levered Free Cash Flow (TTM) | -68.48 M |
| Return on Assets (TTM) | -30.87% |
| Return on Equity (TTM) | -48.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Oric Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | -0.20 |
|
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.56% |
| % Held by Institutions | 123.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nextech Invest, Ltd. | 31 Mar 2025 | 5,285,714 |
| Nextech Invest Ltd. | 31 Dec 2024 | 5,285,714 |
| Alkeon Capital Management Llc | 31 Mar 2025 | 4,004,096 |
| Column Group Llc | 31 Mar 2025 | 3,540,777 |
| Ecor1 Capital, Llc | 31 Mar 2025 | 3,418,068 |
| Vivo Capital, Llc | 31 Mar 2025 | 2,080,450 |
| Silverarc Capital Management, Llc | 31 Mar 2025 | 2,060,240 |
| First Turn Management, Llc | 31 Mar 2025 | 2,027,430 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (HC Wainwright & Co., 143.63%) | Buy |
| Median | 17.00 (88.26%) | |
| Low | 12.00 (Oppenheimer, 32.89%) | Buy |
| Average | 17.00 (88.26%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 May 2025 | 22.00 (143.63%) | Buy | 5.08 |
| 05 May 2025 | 21.00 (132.56%) | Buy | 5.70 | |
| Oppenheimer | 06 May 2025 | 12.00 (32.89%) | Buy | 5.04 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PISCITELLI DOMINIC | - | 9.58 | -6,200 | -58,294 |
| Aggregate Net Quantity | -6,200 | |||
| Aggregate Net Value ($) | -58,294 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 9.58 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PISCITELLI DOMINIC | Officer | 11 Jun 2025 | Automatic sell (-) | 2,976 | 9.39 | 27,945 |
| PISCITELLI DOMINIC | Officer | 10 Jun 2025 | Automatic sell (-) | 324 | 9.75 | 3,159 |
| PISCITELLI DOMINIC | Officer | 09 Jun 2025 | Automatic sell (-) | 300 | 9.86 | 2,958 |
| PISCITELLI DOMINIC | Officer | 06 Jun 2025 | Automatic sell (-) | 2,600 | 9.32 | 24,232 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |